Literature DB >> 12901235

Cilengitide Merck.

Jeffrey W Smith1.   

Abstract

Merck KGaA is developing cilengitide, the lead in a series of integrin antagonists with anti-angiogenic activities, for the potential treatment of a variety of cancer types. The National Cancer Institute is conducting clinical trials of cilengitide. In October 1999, phase II trials in non-small-cell lung cancer (as a monotherapy) and pancreatic cancer (in combination with gemcitabine) were initiated. These were ongoing in February 2002, by which time, a phase I trial and a phase I/II trial in glioblastoma were underway.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12901235

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  23 in total

Review 1.  Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis?

Authors:  Roland Haubner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

2.  Inter-heterogeneity and intra-heterogeneity of αvβ3 in non-small cell lung cancer and small cell lung cancer patients as revealed by 68Ga-RGD2 PET imaging.

Authors:  Fei Kang; Zhe Wang; Guoquan Li; Shengjun Wang; Daliang Liu; Mingru Zhang; Mingxuan Zhao; Weidong Yang; Jing Wang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-12       Impact factor: 9.236

3.  Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review).

Authors:  Lena J Gamble; Anton V Borovjagin; Qiana L Matthews
Journal:  Exp Ther Med       Date:  2010-03       Impact factor: 2.447

4.  End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma.

Authors:  Warren P Mason
Journal:  Neuro Oncol       Date:  2015-02-13       Impact factor: 12.300

5.  Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity.

Authors:  Ashley Browne; Laura A Tookman; Carin K Ingemarsdotter; Russell D Bouwman; Katrina Pirlo; Yaohe Wang; Iain A McNeish; Michelle Lockley
Journal:  Cancer Res       Date:  2015-05-14       Impact factor: 12.701

6.  Integrin alpha(v)beta(3)-Targeted Cancer Therapy.

Authors:  Zhaofei Liu; Fan Wang; Xiaoyuan Chen
Journal:  Drug Dev Res       Date:  2008       Impact factor: 4.360

7.  Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.

Authors:  L Burt Nabors; Karen L Fink; Tom Mikkelsen; Danica Grujicic; Rafal Tarnawski; Do Hyun Nam; Maria Mazurkiewicz; Michael Salacz; Lynn Ashby; Vittorina Zagonel; Roberta Depenni; James R Perry; Christine Hicking; Martin Picard; Monika E Hegi; Benoit Lhermitte; David A Reardon
Journal:  Neuro Oncol       Date:  2015-03-11       Impact factor: 12.300

Review 8.  The tumor microenvironment and its contribution to tumor evolution toward metastasis.

Authors:  Girieca Lorusso; Curzio Rüegg
Journal:  Histochem Cell Biol       Date:  2008-11-06       Impact factor: 4.304

9.  Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.

Authors:  Mustafa Khasraw; Adrian Lee; Sally McCowatt; Zoltan Kerestes; Marc E Buyse; Michael Back; Ganessan Kichenadasse; Stephen Ackland; Helen Wheeler
Journal:  J Neurooncol       Date:  2016-03-02       Impact factor: 4.130

Review 10.  Current status and future directions of anti-angiogenic therapy for gliomas.

Authors:  Wolfgang Wick; Michael Platten; Antje Wick; Anne Hertenstein; Alexander Radbruch; Martin Bendszus; Frank Winkler
Journal:  Neuro Oncol       Date:  2015-10-12       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.